Protalix BioTherapeutics, Inc. (PLX) Financial Statements (2024 and earlier)

Company Profile

Business Address 2 UNIVERSITY PLAZA
HACKENSACK, NJ 07601
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments48,18433,03617,11110,72012,49216,888
Cash and cash equivalents48,18433,03617,11110,72012,49216,888
Receivables4,0491,3044,5868,6512,0225,908
Inventory, net of allowances, customer advances and progress billings19,63520,30316,80414,56216,50716,594
Inventory19,63520,30316,80414,56216,50716,594
Other current assets1,7087581,3101,7362,5971,123
Other undisclosed current assets  5,06910,09116,08216,029
Total current assets:73,57655,40144,88045,76049,70056,542
Noncurrent Assets
Operating lease, right-of-use asset5,8065,2025,0874,8544,7694,903
Property, plant and equipment4,6374,7044,5534,6774,7684,894
Deferred income tax assets3,130     
Other undisclosed noncurrent assets1,2681,2521,2671,4181,4032,052
Total noncurrent assets:14,84111,15810,90710,94910,94011,849
TOTAL ASSETS:88,41766,55955,78756,70960,64068,391
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities18,54518,57612,27118,50919,65422,287
Accounts payable18,54518,57612,27118,50919,65422,287
Deferred revenue  11,79013,17814,79310,22311,801
Debt      
Other undisclosed current liabilities4,5641,1496,9801,0001,0831,243
Total current liabilities:23,10931,51532,42934,30230,96035,331
Noncurrent Liabilities
Long-term debt and lease obligation 20,13228,26728,18732,14231,92632,155
Long-term debt, excluding current maturities 20,13228,26728,18728,11128,03327,962
Liabilities, other than long-term debt6,1755,7695,8111,7797,6438,391
Deferred revenue     5,8955,895
Liability, pension and other postretirement and postemployment benefits1,5981,6171,6421,7791,7482,496
Operating lease, liability4,5774,1524,1694,0313,8934,193
Total noncurrent liabilities:26,30734,03633,99833,92139,56940,546
Total liabilities:49,41665,55166,42768,22370,52975,877
Equity
Equity, attributable to parent, including:39,0011,008(10,640)(11,514)(9,889)(7,486)
Common stock   54   
Additional paid in capital   379,167   
Accumulated deficit   (389,861)   
Other undisclosed equity, attributable to parent39,0011,008 (11,514)(9,889)(7,486)
Total equity:39,0011,008(10,640)(11,514)(9,889)(7,486)
TOTAL LIABILITIES AND EQUITY:88,41766,55955,78756,70960,64068,391

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues35,0759,5888,61714,1838,75316,085
Cost of revenue(6,148)(3,085)(2,397)(7,074)(4,087)(6,034)
Gross profit:28,9276,5036,2207,1094,66610,051
Operating expenses(8,506)(8,962)(8,715)(10,234)(10,190)(11,921)
Operating income (loss):20,421(2,459)(2,495)(3,125)(5,524)(1,870)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
(774)(477)(715)(442)190(416)
Income (loss) from continuing operations before income taxes:19,647(2,936)(3,210)(3,567)(5,334)(2,286)
Income tax expense(308)(195)    
Other undisclosed loss from continuing operations   (530)   
Income (loss) from continuing operations:19,339(3,131)(3,740)(3,567)(5,334)(2,286)
Loss before gain (loss) on sale of properties:(3,567)(5,334)(2,286)
Net income (loss) available to common stockholders, basic:19,339(3,131)(3,740)(3,567)(5,334)(2,286)
Dilutive securities, effect on basic earnings per share(1,749)     
Net income (loss) available to common stockholders, diluted:17,590(3,131)(3,740)(3,567)(5,334)(2,286)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net income (loss):19,339(3,131)(3,740)(3,567)(5,334)(2,286)
Comprehensive income (loss), net of tax, attributable to parent:19,339(3,131)(3,740)(3,567)(5,334)(2,286)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: